Patents by Inventor Jason Hanko
Jason Hanko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120232303Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.Type: ApplicationFiled: May 11, 2012Publication date: September 13, 2012Applicants: Diatex, Inc., Metabolex, Inc.Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
-
Publication number: 20120202857Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.Type: ApplicationFiled: August 4, 2011Publication date: August 9, 2012Applicant: FERROKIN BIOSCIENCES, INC.Inventors: Amy E. Tapper, Hugh Y. Rienhoff, JR., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
-
Publication number: 20120196895Abstract: The invention relates to novel crystalline forms of (2RS)-1-(4-ethylphenyl)-2-methyl-3-piperidin-1-yl-propan-1-one. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline forms, which are useful to treat and/or prevent various conditions such as pathological muscle contracture, myotonic conditions, and spastic paralysis or spasticity caused by various neurologic conditions, and are also useful for the treatment and/or prevention of various types of pain and pathological muscle tension.Type: ApplicationFiled: January 11, 2010Publication date: August 2, 2012Applicant: Bionevia Pharmaceuticals, Inc.Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Jeffrey S. Stults, Jason A. Hanko
-
Publication number: 20120190817Abstract: The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I.Type: ApplicationFiled: July 12, 2011Publication date: July 26, 2012Applicant: Celgene CorporationInventors: Jason Hanko, David Engers, Eric Hagen, Valeriya Smolenskaya, Jeffrey Stults
-
Patent number: 8203019Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.Type: GrantFiled: April 20, 2006Date of Patent: June 19, 2012Assignees: Metabolex, Inc., DiaTex, Inc.Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
-
Publication number: 20120046442Abstract: The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I.Type: ApplicationFiled: July 12, 2011Publication date: February 23, 2012Inventors: Jason Hanko, David Alan Engers, Eric Hagen, Valenya Smolenskaya, Jeffrey Scott Stults
-
Publication number: 20120029008Abstract: The present invention is directed to novel crystalline and amorphous forms of nalbuphine hydrochloride.Type: ApplicationFiled: July 21, 2011Publication date: February 2, 2012Inventors: Jason Hanko, Petinka Vlahova
-
Patent number: 8063227Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.Type: GrantFiled: July 14, 2009Date of Patent: November 22, 2011Assignee: Ferrokin Biosciences, Inc.Inventors: Amy E. Tapper, Hugh Y. Rienhoff, Jr., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
-
Publication number: 20110281911Abstract: The invention relates to substantially enantiopure crystalline salt forms of (2RS)-I-(4-Ethylphenyl)-2-methyl-3-piperidin-1-ylpropan-1-one. The preparation and characterization of the substantially enantiopure crystalline salt forms according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the substantially enantiopure crystalline salt forms, which are useful to treat and/or prevent various conditions such as pathological muscle contracture, myotome conditions, and spastic paralysis or spasticity caused by various neurologic conditions, and are also useful for the treatment and/or prevention of various types of pain and pathological muscle tension.Type: ApplicationFiled: August 3, 2009Publication date: November 17, 2011Applicant: Bionevia Pharmaceuticals, Inc.Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Jeffrey S. Stults, Jason A. Hanko, Jeffrey P. Kiplinger
-
Publication number: 20110275679Abstract: The invention relates to crystalline forms of flupirtine, particularly to 1:1 flupirtine hydrochloride maleic acid cocrystal. The preparation and characterization of 1:1 flupirtine hydrochloride maleic acid cocrystal is described. The invention also relates to the therapeutic use of the flupirtine hydrochloride maleic acid cocrystal to treat nervous system disorders, pain disorders, and musculoskeletal disorders and to pharmaceutical compositions containing the cocrystal.Type: ApplicationFiled: August 6, 2009Publication date: November 10, 2011Applicant: Bionevia Pharmaceuticals, Inc.Inventors: Isabel Kalofonos, Dimitris Kalofonos, Patrick G. Stahly, Jeffrey S. Stults, Jason A. Hanko, Rex A. Shipplett, William Martin-Doyle
-
Publication number: 20110275695Abstract: The invention relates to crystalline forms of zotepine hydrochloride, including the crystalline hydrochloride salt of zotepine and two cocrystals of zotepine hydrochloride with benzoic acid. The preparation and characterization of these crystalline forms of zotepine hydrochloride is described. The invention also relates to the therapeutic use of the crystalline forms of zotepine hydrochloride to treat central nervous system disorders and to pharmaceutical compositions containing them.Type: ApplicationFiled: June 11, 2009Publication date: November 10, 2011Applicant: BIONEVIA PHARMACEUTICALS, INC.Inventors: Isabel Kalofonos, Dimitris Kalofonos, William Martin-Doyle, Jason Hanko, Eric J. Hagen
-
Patent number: 8003684Abstract: Crystalline forms of (+)-R-zileuton, which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of (+)-R-zileuton are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline (+)-R-zileuton, and using it to inhibit 5-lipoxygenase activity in subjects to treat a number of diseases, are also discussed.Type: GrantFiled: February 21, 2007Date of Patent: August 23, 2011Assignee: Cornerstone Therapeutics, Inc.Inventor: Jason A. Hanko
-
Publication number: 20110160257Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.Type: ApplicationFiled: March 7, 2011Publication date: June 30, 2011Applicant: FERROKIN BIOSCIENCES, INC.Inventors: Amy E. Tapper, Hugh Y. Rienhoff, JR., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
-
Publication number: 20100137383Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.Type: ApplicationFiled: July 14, 2009Publication date: June 3, 2010Applicant: FERROKIN BIOSCIENCES, INC.Inventors: Amy E. Tapper, Hugh Y. Rienhoff, JR., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
-
Patent number: 7692038Abstract: The present invention relates to crystalline forms of (3S)-3-[N—(N?-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2?,3?,5?,6?-tetrafluorophenoxy)-4-oxopentanoic acid (see formula I). The invention further relates to pharmaceutical compositions comprising such crystalline forms and to the use of said pharmaceutical compositions and said crystalline forms in the treatment of various conditions, particularly in the treatment of liver fibrosis.Type: GrantFiled: December 6, 2007Date of Patent: April 6, 2010Assignee: Pfizer, Inc.Inventors: Eric Hagen, Jason A. Hanko, Stuart Dimock
-
Publication number: 20080249031Abstract: The present invention relates to crystalline forms of (3S)-3-[N—(N?-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2?,3?,5?,6?-tetrafluorophenoxy)-4-oxopentanoic acid (see formula I). The invention further relates to pharmaceutical compositions comprising such crystalline forms and to the use of said pharmaceutical compositions and said crystalline forms in the treatment of various conditions, particularly in the treatment of liver fibrosis.Type: ApplicationFiled: December 6, 2007Publication date: October 9, 2008Inventors: Eric Hagen, Jason A. Hanko, Stuart Dimock
-
Publication number: 20080221018Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.Type: ApplicationFiled: April 20, 2006Publication date: September 11, 2008Applicant: METABOLEX, INC.Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
-
Publication number: 20070244185Abstract: Crystalline forms of (+)-R-zileuton, which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of (+)-R-zileuton are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline (+)-R-zileuton, and using it to inhibit 5-lipoxygenase activity in subjects to treat a number of diseases, are also discussed.Type: ApplicationFiled: February 21, 2007Publication date: October 18, 2007Inventor: Jason Hanko
-
Patent number: 6872725Abstract: Crystalline forms of the p38 kinase inhibitor N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole are provided. These crystalline forms include (a) a first anhydrous crystalline form possessing improved physical stability relative to other solid-state forms of the compound; (b) a second anhydrous crystalline form possessing unique properties relative to other solid-state forms of the compound; (c) a third anhydrous crystalline form possessing unique properties relative to other solid-state forms of the compound; and (d) solvated crystalline forms, hydrated crystalline forms, and crystalline salt forms of the compound that are useful, for example, as intermediate solid-state forms in the preparation of other crystalline forms of the compound.Type: GrantFiled: September 25, 2002Date of Patent: March 29, 2005Assignee: Pharmacia CorporationInventors: Kimberley C. Allen, Jerry D. Clark, Thomas P. Fraher, Jason A. Hanko, Kimberly L. Kolbert, Clay R. Little, Michael K. Mao, Patricia S. Miyake, Jodi L. Moe, Partha S. Mudipalli, Tobin C. Schilke, Christine B. Seymour, Ahmad Y. Sheikh, Gopichand Yalamanchili
-
Publication number: 20030153583Abstract: Crystalline forms of the p38 kinase inhibitor N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole are provided. These crystalline forms include (a) a first anhydrous crystalline form possessing improved physical stability relative to other solid-state forms of the compound; (b) a second anhydrous crystalline form possessing unique properties relative to other solid-state forms of the compound; (c) a third anhydrous crystalline form possessing unique properties relative to other solid-state forms of the compound; and (d) solvated crystalline forms, hydrated crystalline forms, and crystalline salt forms of the compound that are useful, for example, as intermediate solid-state forms in the preparation of other crystalline forms of the compound.Type: ApplicationFiled: September 25, 2002Publication date: August 14, 2003Inventors: Kimberley C. Allen, Jerry D. Clark, Thomas P. Fraher, Jason A. Hanko, Kimberly L. Kolbert, Clay R. Little, Michael K. Mao, Patricia S. Miyake, Jodi L. Moe, Partha S. Mudipalli, Tobin C. Schilke, Christine B. Seymour, Ahmad Y. Sheikh, Gopichand Yalamanchili